DOI: https://doi.org/10.18370/2309-4117.2020.54.86-88

Vulvovaginal candidiasis therapy in reproductive age women

Т. Г. Романенко, О. М. Суліменко

Abstract


Objective of the study: was to determine the effectiveness of complex therapy with Fusys® (fluconazole, 150 mg tablets) in combination with Clofan® (clotrimazole, vaginal suppositories 500 mg) in the treatment of acute vulvovaginal candidiasis (VVC).

Materials and methods. 38 patients in the age of 22 to 42 were examined for acute VVC. C. albicans fungi were causative agent of VVC in all women. After vaginal candidiasis diagnosis was confirmed, all patients were prescribed oral systemic fluconazole 150 mg (Fusys®) once in combination with a single vaginal administration of Clofan® (clotrimazole, vaginal suppositories 500 mg) for acute VVC treatment. At the same time, they warned of the need to treat a partner (Fusys® gel was prescribed). Effectiveness of treatment was evaluated after 3; 7 and 30 days after therapy. Results. All study participants noted a decrease in the severity of itching and intensity of discharge from the genital tract on the third day after therapy. Clinical symptoms of VVC completely disappeared in 35 (92.1%) women by the end of the seventh day after treatment. Microscopic and cultural examination revealed no Candida fungi in 31 (81.6%) patients. The rest of the women who had candidiasis again were treated by once prescribed oral Fusys® (150 mg) in combination with a single vaginal administration of Clofan® suppositories (500 mg). Repeated microscopic and culture studies carried out after 7 days showed no fungi in these patients.

Conclusion. The effectiveness of VVC complex therapy in the study was 92.1%. The results indicate high clinical and microbiological efficacy of complex therapy in combination with fluconazole (Fusys®) and clotrimazole Clofan® for the VVC treatment in women of reproductive age

Keywords


vulvovaginal candidiasis; Candida albicans; fluconazole; clotrimazole; complex therapy

References


Paladine, H.L., Desai, U.A. “Vaginitis: diagnosis and treatment.” Am Fam Physician 97.5 (2018): 321–9.

Rogovskaya, S.I. “On the question of optimizing the treatment of vulvovaginal candidiasis.” Doctor.ru. Gynecology. Endocrinology 1.89 (2014): 25–32.

Sobel, J.D. “Recurrent vulvovaginal candidiasis.” Am J Obstet Gynecol 214 (2016): 15–21. DOI: 10.1016/j.ajog.2015.06.067

Gonçalves, B., Ferreira, C., Alves, C.T., et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. 2016;42(6):905–927. DOI: 10.3109/1040841X.2015.1091805

Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/cshperspect. a019778

Serov, V.N., Sukhikh, G.T., Prilepskaya, V.N., Radzinsky, V.E., eds. Guidelines for outpatient care in obstetrics and gynecology. Moscow. GEOTAR-Media (2016): 1136 p.

Prilepskaya, V.N., Bayramova G.R. Vulvovaginal candidiasis. Clinical picture, diagnostics, principles of therapy. Moscow. GEOTAR-Media (2010): 80 p.

Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge (2018).” Int J STD AIDS 29.13 (2018): 1258–72. DOI: 10.1177/0956462418785451

Swidsinski, A., Guschin, A., Tang, Q., et al. “Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms.” Am J Obstet Gynecol 220.1 (2019): 91.e1–91.e8. DOI: 10.10.

Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/ cshperspect. a019778

Palmeira-de-Oliveira, R., Palmeira-de-Oliveira, A., Martinez-de-Oliveira, J. “New strategies for local treatment of vaginal infections.” Advanced Drug Delivery Reviews 92 (2015): 105–22. DOI: 10.1016/j.addr.2015.06.008

Sardi, J.C.O., Scorzoni, L., Bernardi, T., et al. “Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.” J Med Microbiol 62.1 (2013): 10–24. DOI: 10.1099/jmm.0.045054-0

Deorukhkar, S.C., Saini, S., Mathew, S. “Non-albicans Candida Infection: An Emerging Threat.” Interdiscip Perspect Infect Dis 2014 (2014): 615958. DOI: 10.1155/2014/615958

Nobile, C.J., Johnson, A.D. “Candida albicans biofilms and human disease.” Annu Rev Microbiol 69 (2015): 71–92. DOI: 10.1146/annurev-micro-091014-104330

Ramage, G., Rajendran, R., Sherry, L., Williams, C. “Fungal biofilm resistance.” Int J Microbiol 2012 (2012): 528521. DOI: 10.1155/2012/528521

Sherry, L., Kean, R., McKloud, E., et al. “Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole.” Antimicrob Agents Chemother 61.9 (2017): e01065–17. DOI: 10.1128/AAC.01065-17

Blostein, F., Levin-Sparenberg, E., Wagner, J., Foxman, B. “Recurrent vulvovaginal candidiasis.” Annals of Epidemiology 27.9 (2017): 575–82. DOI: 10.1016/j. annepidem.2017.08.010

Mgeryan, A.N. “Vulvovaginal candidiasis: the effectiveness of clotrimazole therapy.” Effective pharmacotherapy 15.26 (2019): 36–41. DOI: 10.33978/2307-3586-2019-15-26-36-41

Roberts, C., Algert, C., Morris, J., Rickard, K. “Treating vaginal candidiasis for the prevention of preterm birth: protocol for a systematic review and metaanalysis.” Systematic Review 4 (2015): 31. DOI: 10.1186/s13643-015-0018-2

Workowski, K.A., Bolan, G.A. “Sexually transmitted diseases treatment guidelines, 2015.” The MMWR Recommendations and Reports 64.RR3 (2015): 1–137.


GOST Style Citations


1.      Paladine, H.L., Desai, U.A. “Vaginitis: diagnosis and treatment.” Am Fam Physician 97.5 (2018): 321–9.

2.      Роговская, С.И. К вопросу об оптимизации лечения вульвовагинального кандидоза / С.И. Роговская // Доктор.ру. Гинекология. Эндокринология. – 2014. – № 1 (89). – С. 25–32.

3.      Sobel, J.D. “Recurrent vulvovaginal candidiasis.” Am J Obstet Gynecol 214 (2016): 15–21. DOI: 10.1016/j.ajog.2015.06.067

4.      Gonçalves, B., Ferreira, C., Alves, C.T., et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. 2016;42(6):905–927. DOI: 10.3109/1040841X.2015.1091805

5.      Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/cshperspect. a019778

6.      Серов, В.Н., ред. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии / под ред. В.Н. Серова, Г.Т. Сухих, В.Н. Прилепской, В.Е. Радзинского. – М.: ГЭОТАР-Медиа, 2016. – 1136 с.

7.      Прилепская, В.Н. Вульвовагинальный кандидоз. Клиника, диагностика, принципы терапии / В.Н. Прилепская, Г.Р. Байрамова. – М.: ГЭОТАР-Медиа, 2010. – 80 с.

8.      Sherrard, J., Wilson, J., Donders, G., et al. “European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge (2018).” Int J STD AIDS 29.13 (2018): 1258–72. DOI: 10.1177/0956462418785451

9.      Swidsinski, A., Guschin, A., Tang, Q., et al. “Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms.” Am J Obstet Gynecol 220.1 (2019): 91.e1–91.e8. DOI: 10.10.

10.    Turner, S.A., Butler, G. “The candida pathogenic species complex.” Cold Spring Harb Perspect Med 4.9 (2014): a019778. DOI: 10.1101/ cshperspect. a019778

11.    Palmeira-de-Oliveira, R., Palmeira-de-Oliveira, A., Martinez-de-Oliveira, J. “New strategies for local treatment of vaginal infections.” Advanced Drug Delivery Reviews 92 (2015): 105–22. DOI: 10.1016/j.addr.2015.06.008

12.    Sardi, J.C.O., Scorzoni, L., Bernardi, T., et al. “Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.” J Med Microbiol 62.1 (2013): 10–24. DOI: 10.1099/jmm.0.045054-0

13.    Deorukhkar, S.C., Saini, S., Mathew, S. “Non-albicans Candida Infection: An Emerging Threat.” Interdiscip Perspect Infect Dis 2014 (2014): 615958. DOI: 10.1155/2014/615958

14.    Nobile, C.J., Johnson, A.D. “Candida albicans biofilms and human disease.” Annu Rev Microbiol 69 (2015): 71–92. DOI: 10.1146/annurev-micro-091014-104330

15.    Ramage, G., Rajendran, R., Sherry, L., Williams, C. “Fungal biofilm resistance.” Int J Microbiol 2012 (2012): 528521. DOI: 10.1155/2012/528521

16.    Sherry, L., Kean, R., McKloud, E., et al. “Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole.” Antimicrob Agents Chemother 61.9 (2017): e01065–17. DOI: 10.1128/AAC.01065-17

17.    Blostein, F., Levin-Sparenberg, E., Wagner, J., Foxman, B. “Recurrent vulvovaginal candidiasis.” Annals of Epidemiology 27.9 (2017): 575–82. DOI: 10.1016/j. annepidem.2017.08.010

18.    Мгерян, А.Н. Вульвовагинальный кандидоз: эффективность терапии клотримазолом / А.Н. Мгерян // Эффективная фармакотерапия. – 2019. – Т. 15, № 26. – С. 36–41.

19.    Roberts, C., Algert, C., Morris, J., Rickard, K. “Treating vaginal candidiasis for the prevention of preterm birth: protocol for a systematic review and metaanalysis.” Systematic Review 4 (2015): 31. DOI: 10.1186/s13643-015-0018-2

20.    Workowski, K.A., Bolan, G.A. “Sexually transmitted diseases treatment guidelines, 2015.” The MMWR Recommendations and Reports 64.RR3 (2015): 1–137.





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)